Abstract: The present invention is described as a lipid-complexed topoisomerase I inhibitor (TII), for example camptothecin (CPT) preparation that allows for intravenous administration in vivo in clinically relevant lipid:drug ratios. The lipid formulation has in vitro antitumor activity similar to that of the base compound and displays similar cytotoxicity against both MDR-1 negative and positive tumor cells.
Type:
Grant
Filed:
May 3, 1995
Date of Patent:
November 10, 1998
Assignees:
Roman Perez-Soler, Steven M. Sugarman, Kenneth R. Poirot
Inventors:
Roman Perez-Soler, Steven M. Sugarman, Kenneth R. Poirot